To Get Full Access :

aBLA Filing Intelligence & Biosimilar Opportunity

Ebglyss

Lebrikizumab-Lbkz
Immunomodulators
Prefilled Pen Subcutaneous Injection

Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.

Approval Date
13-Sep-24
Data Exclusivity Expiry
13-Sep-28
Market Exclusivity Expiry
13-Sep-36
Commercial snapshot

Market performance & projections

Revenue ($M)
533
CAGR (%)
40.77%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
884
2027
1,267
2028
1,696
2029
2,093
2030
2,436
2031
2,737
2032
3,009
Molecule profile

Details & specifications

Molecule
Lebrikizumab-Lbkz
Innovator
ELI LILLY
Dosage Form
Prefilled Pen Subcutaneous Injection
Strength
250 mg
Therapeutic Category
Immunomodulators
Usage
To treat moderate-to-severe atopic dermatitis
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?